Idiopathic Intracranial Hypertension

• Impaired CSF Absorption as Primary Mechanism: The arachnoid granulations and dural venous sinuses, the primary sites of CSF absorption into the venous system, demonstrate reduced clearance capacity in IIH. At the cellular level, the arachnoid villi—comprised of endothelial cells with tight junctions and aquaporin-4 water channels—show altered expression of aquaporin-4, reduced tight junction protein expression (occludin, claudin-5, and zonula occludens-1), and impaired transepithelial water transport. Phosphodiesterase-5 inhibitors and other agents that increase cyclic guanosine monophosphate (cGMP) appear to restore tight junction integrity and improve CSF absorption. The dural venous sinuses, particularly the transverse and sigmoid sinuses, demonstrate reduced luminal diameter and increased collapsibility in IIH patients, creating a "venous stenosis" that impedes CSF absorption into the systemic circulation. This venous narrowing may be secondary to CSF pressure elevation rather than primary but perpetuates the cycle of elevated ICP.

• CSF Production Dysregulation and Choroid Plexus Dysfunction: The choroid plexus epithelium actively produces CSF through active ion secretion (primarily sodium transport via Na+-K+-ATPase) coupled with aquaporin-1-mediated water movement. In IIH, choroid plexus aquaporin-1 expression and Na+-K+-ATPase activity may be dysregulated, though production itself is typically normal or only mildly elevated. However, altered expression of tight junction proteins within the blood-brain barrier and choroid plexus may impair glymphatic system function and reduce interstitial fluid-CSF exchange, effectively increasing net fluid accumulation within the cranial vault.

• Altered Intracranial Compliance and the Monro-Kellie Doctrine: The skull is a rigid compartment containing three components: brain parenchyma, blood volume, and CSF. When CSF accumulates, compensatory mechanisms occur through displacement of blood into the spinal compartment and compression of periventricular tissue. However, the compliance (ability to accommodate volume changes) becomes exhausted rapidly—small increases in volume produce large increases in pressure (the steep portion of the pressure-volume curve). The elevated pressure is transmitted throughout the intracranial compartment, affecting the optic nerves and their blood supply.

• Obesity-Related Mechanisms: Obesity fundamentally alters multiple systems relevant to ICP regulation. Elevated intra-abdominal pressure in obese individuals increases intrathoracic pressure via Valsalva effect, reducing venous return and impairing CSF absorption. Obesity-associated insulin resistance increases cerebrospinal fluid lactate and alters glymphatic function. Leptin resistance in obesity correlates with IIH severity. Increased sex steroid sensitivity in adipose tissue and altered renin-angiotensin-aldosterone system (RAAS) activation promote fluid retention and increased intravascular volume, elevating venous pressure and reducing the pressure gradient for CSF absorption.

• Endocrine and Metabolic Dysregulation: Abnormal estrogen metabolism, vitamin A dysregulation (hypervitaminosis A or altered vitamin A handling), and altered thyroid hormone metabolism have been implicated. Vitamin A is known to affect tight junction proteins and cellular differentiation; excessive vitamin A, typically in the context of isotretinoin therapy or supplementation, can precipitate IIH-like syndrome. The mechanism may involve altered retinoic acid receptor signaling affecting epithelial barrier function.

• Neurogenic and Glymphatic System Dysfunction: Contemporary evidence suggests impaired glymphatic system function—the process by which aquaporin-4-mediated fluid flow along perivascular spaces clears interstitial waste products. Dysfunction of perivascular aquaporin-4 channels impairs this system, leading to interstitial fluid accumulation and effective increase in CNS volume within the rigid cranial vault.

• Obesity (Primary Risk Factor): Obesity, defined as body mass index (BMI) >30 kg/m², is present in approximately 70-90% of IIH cases and represents the most significant modifiable risk factor. The relationship between obesity and IIH is remarkably consistent across populations; notably, weight loss of 5-10% can reduce intracranial pressure and improve papilledema. The mechanism involves increased intra-abdominal pressure, venous insufficiency, altered metabolic hormones, and glymphatic dysfunction. Even in non-obese patients with IIH, subclinical features of metabolic syndrome (insulin resistance, dyslipidemia) are often present.

• Female Reproductive Status and Estrogen Exposure: Women of childbearing age (18-40 years) comprise 85-90% of IIH cases, with a marked female predominance suggesting sex hormone dependence. Exogenous estrogen exposure through oral contraceptives and hormone replacement therapy significantly increases risk; retrospective studies demonstrate a 2-10 fold increased risk in users of combined hormonal contraceptives compared to non-users. Menarche, pregnancy, and perimenopause are common temporal relationships. The precise mechanism involves altered estrogen receptor signaling in cerebrovascular and glymphatic systems, increased fluid retention through estrogen-mediated RAAS activation, and altered vitamin A metabolism.

• Medications Associated with Secondary IIH:
• Tetracyclines (doxycycline, minocycline): Class effect, risk increases with dosing and duration; mechanism involves immune modulation
• Isotretinoin (Accutane): Hypervitaminosis A-related; commonly encountered in dermatology patients
• Corticosteroids: Paradoxically, both initiation and withdrawal have been associated
• Hormonal contraceptives and HRT: As above
• Nalidixic acid and other fluoroquinolones: Rare
• Lithium: Mechanism unclear, possible interference with fluid homeostasis
• Vitamin A and derivatives: Retinoids in any form; toxicity threshold ~100,000-500,000 IU daily

• Metabolic and Endocrine Conditions:
• Hyperthyroidism and thyroid dysfunction
• Polycystic ovary syndrome (PCOS): Represents insulin resistance, androgen excess, and potential estrogen exposure
• Hypoparathyroidism
• Addison's disease
• Cushing's syndrome

• Hematologic and Vascular Disorders:
• Cerebral venous sinus thrombosis (CVST): Can present identically to IIH with elevated CSF pressure; requires exclusion by venography/MRV
• Dural sinus stenosis: Distinction between this and IIH remains debated; some regard it as a form of IIH pathophysiology, others as a separate entity
• Polycythemia vera: Increased blood viscosity
• Iron deficiency anemia: Possible compensatory mechanisms (unexplained relationship)
• Systemic lupus erythematosus: Associated with antiphospholipid syndrome and thrombophilia

• Neuro-Otologic Conditions (Risk Factor Associations):
• Chronic rhinosinusitis and nasal obstruction: Potential mechanism through increased venous pressure from impaired venous drainage
• Sleep apnea: Hypercapnia and intermittent hypoxemia elevation

• Prior Head Trauma or Infection: Rare associations; mechanism unclear

• Vitamin A Intoxication: Either from supplementation or from conditions causing hypervitaminosis A (hepatic disease with vitamin A mobilization)

• Headache (Most Common Presenting Symptom, 85-95% of Cases): Headache in IIH is characteristically diffuse, non-focal, and progressive over weeks to months. The pain is typically worse in the morning upon awakening and with Valsalva maneuvers (straining, bearing down, coughing, bending). The morning predominance reflects supine position and reduced venous drainage overnight, allowing CSF pressure to accumulate. The headache may mimic migraine in quality but differs in its consistent positional and exertional worsening and lack of unilateral features. Patients often describe pressure-like, throbbing, or band-like pain. The headache may be generalized or disproportionately worse in the vertex or occipital regions. Importantly, the severity of headache does not correlate with the degree of elevated intracranial pressure—some patients with severe IIH have minimal headache, while others with mild pressure elevation have debilitating pain, suggesting that individual variance in pain perception and meningeal irritation contribute.

• Vision Changes (Critical Manifestation; 25-50% at Presentation, Up to 100% if Untreated):
• Obscurations of vision (transient visual loss): Stereotypical, described as brief (seconds to 1 minute) episodes of complete darkness affecting both eyes simultaneously or dimming of vision, often triggered by postural changes or Valsalva. These represent transient ischemia of the optic nerve head related to elevated ICP compromising optic nerve perfusion pressure. Obscurations are an ominous sign indicating impending permanent vision loss and demand urgent treatment.
• Peripheral visual field defects: Characteristically enlargement of the blind spot (scotoma), arcuate (nerve fiber bundle) defects, or generalized concentric visual field constriction reflecting compression of the optic nerve axons by papilledema
• Diplopia (horizontal in 25-30% of cases): Results from impaired abduction reflex from increased ICP affecting CN VI (the longest intracranial course makes CN VI most vulnerable to mass effect and pressure elevation); typically bilateral and causing horizontal diplopia worse on lateral gaze toward affected side
• Photopsia or photopsia: Transient visual phenomena
• Reduced visual acuity: Late finding, generally indicates chronic papilledema with permanent optic nerve damage

• Transient Visual Obscurations (TVOs): These warrant special emphasis as a hallmark of IIH. TVOs are brief, complete darkening of vision affecting both eyes, lasting seconds to 1 minute, often described as a "grey-out," "black-out," or "lights dimming." They occur with position changes (standing, lying down), Valsalva maneuvers (straining, coughing), or exertion. TVOs represent prodromal symptoms indicating imminent permanent vision loss if treatment is not initiated and carry major prognostic significance.

• Neck and Shoulder Pain/Stiffness: Reported in 15-40% of cases, presumably due to increased CSF pressure affecting the spinal dura and surrounding structures; may superficially resemble meningitis but CSF studies are normal

• Pulsatile Tinnitus: Reported in 30-60% of cases. This synchronous with pulse beat sound in the ear reflects elevated ICP transmitted to the dural venous sinuses and petrous temporal bone structures, causing vibrations in the perilymph; resolves with successful ICP reduction

• Auditory Manifestations: Some patients report hearing loss or hyperacusis (elevated hearing sensitivity), suggesting increased pressure transmitted along the Aqua cochleae (cochlear aqueduct) to the inner ear structures

• Physical Examination Findings:
• Papilledema: The pathognomonic finding; represents optic disc swelling from compression of axoplasmic flow in optic nerve fibers by increased subarachnoid pressure. Stages of papilledema (Frisén scale or traditional grading):
• Stage I: Blurring of nasal disc margin
• Stage II: Blurring of all margins, obscuration of cup
• Stage III: Elevation of disc edges, obliteration of margins, beginning obscuration of vessels
• Stage IV: Complete obscuration of vessels on disc, elevated disc
• Stage V: Total whitening of disc (rare, indicates severe chronic papilledema)

• Enlarged Blind Spot on Perimetry: Enlargement of the physiologic blind spot to >6 degrees horizontally on automated perimetry reflects early papilledema; this may be the first detectable visual field abnormality

• Abducens Nerve Palsy (CN VI): Bilateral or unilateral impaired abduction, causing horizontal diplopia. CN VI has the longest intracranial course and is most vulnerable to increased ICP causing a "false localizing sign." This finding, while classic, is actually uncommon (1-3% of IIH cases), but when present strongly suggests elevated ICP.

• Sixth Nerve Findings: Unilateral or bilateral CN VI palsy manifests as inability to abduct the eye(s) beyond midline, causing esotropia on primary gaze and horizontal binocular diplopia worse on lateral gaze.

• Otherwise Normal Neurologic Examination: Critically, the neurologic examination is otherwise entirely normal—no focal deficits, normal strength, normal reflexes, normal sensory function. Presence of focal neurologic deficits should prompt investigation for structural disease.

• Important Clinical Variants:
• IIH without papilledema: Rare (~5% of cases); defined by elevated CSF pressure (>250 mmH₂O) on LP with normal imaging and normal ophthalmologic examination. This variant may have a worse prognosis because lack of papilledema delays recognition.
• Fulminant IIH: Rapid deterioration with acute vision loss over days to weeks; unusual presentation but represents medical emergency
• IIH in children and adolescents: Distinct demographics; often associated with prior otitis media or mastoiditis; may have higher rates of permanent vision loss; can occur in non-obese children
• IIH in men: Comprise 10-15% of cases; more likely to be non-obese, more likely to be underdiagnosed, may present later with more severe vision loss

• Diagnostic Criteria (Modified Dandy Criteria 2013 for IIH):

1. 1.Elevated intracranial pressure (opening pressure >250 mmH₂O in non-obese patients, >280 mmH₂O in obese patients) documented on lumbar puncture performed in recumbent position
2. 2.Absence of other causes of intracranial hypertension on imaging (see below)
3. 3.Absence of focal signs on neurologic examination except for CN VI palsy, transient visual obscurations, photopsia, or visual field defect related to papilledema
4. 4.Alert and oriented mental status (no encephalopathy or decline in consciousness)

Immediate stabilisation (fulminant IIH — severe or rapidly progressive vision loss over days)

• Emergency escalation: admit, start high-dose carbonic anhydrase inhibitor intravenously, and arrange urgent surgical CSF diversion or optic nerve sheath fenestration. A temporising lumbar drain may bridge to surgery. Vision lost to infarcted optic nerve does not return, so decisions are made in hours to days, not weeks.

First-line therapy for typical (non-fulminant) disease

• Weight loss: a sustained reduction of roughly 5–10% of body weight lowers ICP and can resolve papilledema; every major consensus statement (including the multidisciplinary UK/European IIH consensus guidance) treats it as disease-modifying, not adjunctive. Refer for structured weight management; bariatric surgery outperformed community dietary programs in randomised data for women with IIH and obesity.
• Carbonic anhydrase inhibitors — acetazolamide: first-line pharmacotherapy, reducing choroid plexus CSF secretion by blocking bicarbonate generation. The NIH-funded Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) showed acetazolamide plus a weight-loss diet improved visual field function versus diet alone in mild visual loss; dosing is titrated upward as tolerated.
• Remove the precipitant: stop tetracyclines, retinoids/vitamin A, and combined hormonal contraceptives; substitute non-offending agents.

Second-line and escalation

• Topiramate: weak carbonic anhydrase activity plus appetite suppression and migraine benefit; useful when acetazolamide is not tolerated.
• Furosemide: loop diuretic, occasionally added to acetazolamide.
• Headache-directed therapy: treat coexisting migraine and medication-overuse headache separately — headache often persists after ICP normalises.

Definitive/surgical options (failing medical therapy or progressive field loss)

• Optic nerve sheath fenestration: preferred when vision loss dominates.
• CSF shunting (ventriculoperitoneal preferred over lumboperitoneal): preferred when intractable headache dominates.
• Venous sinus stenting: for documented transverse sinus stenosis with a significant trans-stenotic pressure gradient.

Avoid

• Chronic corticosteroids: rebound intracranial hypertension and weight gain on withdrawal; reserve only as a short bridge.
• Serial lumbar punctures as maintenance therapy: relief is transient since CSF reaccumulates within hours.
• Topiramate in pregnancy: teratogenic (oral clefts); acetazolamide use in pregnancy requires specialist input.

Disease-related

• Permanent vision loss from secondary optic atrophy (the principal morbidity): chronic papilledema stagnates axoplasmic flow and compromises prelaminar optic nerve head perfusion, causing axonal death. Signalled by progressive constriction on automated perimetry, loss of the previously swollen disc's hyperemia with pallor, and — late — reduced acuity and a relative afferent pupillary defect if asymmetric.
• Fulminant IIH (emergency): precipitous field and acuity loss over days, often with dense papilledema and macular exudates; requires immediate surgical decompression.
• Transient visual obscurations: harbinger of infarction, not a benign symptom — treat as a red flag for escalation.
• Abducens palsy: false localising sign from nerve stretch over the petrous ridge; produces horizontal diplopia that typically resolves with ICP control.
• Chronic disabling headache: frequently persists after papilledema resolves; medication-overuse headache is a common superimposed complication.
• Recurrence with weight regain or repeat pregnancy.

Treatment-related

• Acetazolamide: non-anion-gap hyperchloremic metabolic acidosis from renal bicarbonate wasting, with paresthesias, fatigue, hypokalemia, and dysgeusia (carbonated drinks taste flat); alkaline urine predisposes to calcium phosphate nephrolithiasis. Rare idiosyncratic aplastic anemia and Stevens–Johnson syndrome are emergencies.
• Topiramate: nephrolithiasis, cognitive slowing/word-finding difficulty, oligohidrosis, and acute angle-closure glaucoma from ciliary body swelling — sudden painful red eye with blurred vision is an ophthalmologic emergency; teratogenic.
• CSF shunt: obstruction, infection/ventriculitis (fever, meningismus, shunt-tract tenderness — emergency), over-drainage causing low-pressure orthostatic headache or subdural hematoma, and acquired tonsillar descent with lumboperitoneal shunts; revision rates are high.
• Optic nerve sheath fenestration: orbital hemorrhage, diplopia from extraocular muscle injury, and rare central retinal artery occlusion with sudden painless vision loss (emergency).
• Venous sinus stenting: requires dual antiplatelet therapy; in-stent or adjacent-segment restenosis with symptom recurrence.
• Post-LP: low-pressure headache and, rarely, CSF leak.

• The stem is nearly always the same: an obese woman of childbearing age with daily headache, pulsatile tinnitus, transient visual obscurations, and bilateral papilledema, with an otherwise normal neurologic exam.
• Single best next step is neuroimaging before lumbar puncture: MRI brain with MR venography excludes mass lesion, hydrocephalus, and cerebral venous sinus thrombosis. Only then perform LP for opening pressure and CSF composition. Choosing LP first is the classic wrong answer.
• Buzzword imaging findings: empty sella, flattening of the posterior globe, distension and tortuosity of the perioptic subarachnoid spaces, and transverse sinus stenosis. These support but do not establish the diagnosis.
• CSF must be normal: elevated opening pressure with normal cell count, glucose, and protein. Abnormal CSF composition means you are looking at meningitis, carcinomatous meningitis, or another secondary cause — not IIH.
• The association examiners love: drug-induced pseudotumor from tetracyclines (doxycycline, minocycline), isotretinoin/vitamin A excess, growth hormone, and combined hormonal contraceptives. An acne patient on doxycycline or isotretinoin with new headache and papilledema is the intended trigger.
• Monitor visual fields, not visual acuity: serial automated (Humphrey) perimetry detects the enlarged blind spot and arcuate/nasal defects long before acuity drops. Acuity loss is a late, ominous finding.
• Headache severity does not track ICP, and CN VI palsy is a false localising sign — its presence does not mean a posterior fossa lesion.
• Management pearl: weight loss plus acetazolamide is first-line; papilledema with progressive field loss escalates to optic nerve sheath fenestration or CSF shunting. Distractors to avoid: chronic steroids (rebound on taper), repeated LPs as maintenance therapy, and dismissing the presentation as migraine when papilledema is present.